Onapgo also doesn't need to be metabolized in the gut first, which ideally gives patients more control over their treatment and its efficacy. "As Parkinson’s disease progresses, ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous ...

Onapgo is a wearable subcutaneous (SC) infusion device that delivers apomorphine, a non-ergoline dopamine agonist, on a continuous basis. Apomorphine is believed to treat “off” episodes ...

The company launched ONAPGO, a subcutaneous apomorphine infusion device for advanced Parkinson’s disease, early in Q2. Initial physician response has been positive, with over 100 prescribers ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a planned Q2 launch. Learn more on SUPN stock here.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that helps ...

ONAPGO will be available in the U.S. by the second quarter of 2025, supported by a nurse education program and access assistance. This approval is a significant step forward in providing patients ...

Onapgo, a device secured to the body by an elastic band worn around the waist, has had a rocky regulatory journey leading up to its FDA nod. Supernus applications seeking regulatory approval were ...

Discover key earnings insights from Supernus Pharmaceuticals Q1 2025 call, highlighting 26% core product growth, ONAPGO launch, and robust strategic focus.